clobetasol and Stomatitis--Aphthous

Amlexanox appears to be most effective overall. Amlexanox 5% paste reduces ulcer size, pain duration, and healing time.

Topics: Administration, Topical; Aminopyridines; Anti-Allergic Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Beclomethasone; Cautery; Clobetasol; Eupatorium; Humans; Mouthwashes; Pain; Phytotherapy; Plant Preparations; Secondary Prevention; Stomatitis, Aphthous; Vitamin B 12

Topics: Adult; Anti-Inflammatory Agents; Clobetasol; Double-Blind Method; Female; Humans; Lacticaseibacillus rhamnosus; Male; Middle Aged; Pain; Patient Satisfaction; Probiotics; Quality of Life; Stomatitis, Aphthous; Surveys and Questionnaires; Young Adult

Aphthous ulceration is a common side effect of sirolimus. These lesions of the oral mucous membranes are often painful and debilitating, leading to either dose reduction or discontinuation of sirolimus in a significant number of patients. We report that the direct application of clobetasol, a high potency topical steroid, led to prompt resolution of the aphthous ulcers that developed in our renal transplant patients on sirolimus-based immunosuppression.

Topics: Adult; Anti-Inflammatory Agents; Clobetasol; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Sirolimus; Stomatitis, Aphthous

To compare the effectiveness of two topical medications to reduce the pain and size of recurrent minor aphthous ulcers.. Ten Colombian Dental Faculties' clinics.. A double-blind randomized multi-centre clinical study.. Ninety-six patients complaining of at least five acute aphthous ulcers were randomized to two intervention groups. Sample size was calculated using an alpha error of 0.05 and beta of 0.20.. Participants were randomly assigned to receive 5% amlexanox or a 0.05% clobetasol propionate magistral preparation. Observers at the participating institutions were previously trained to standardize clinical diagnosis and data recollection. Ulcer size and pain were measured on treatment days 0, 2 and 5.. No significant differences were found between the two groups studied in any of the studied variables at baseline. Both treatment medications significantly reduced pain magnitude and the index ulcer's size on days 2 and 5 compared with day 0 without adverse reactions (within groups differences). No statistical differences between groups of the study medications were found.. The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.

Topics: Aminopyridines; Analysis of Variance; Anti-Allergic Agents; Anti-Inflammatory Agents; Clobetasol; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain Measurement; Stomatitis, Aphthous

We sought to analyze the results of topical treatment with a mouthwash of 0.05% clobetasol in aqueous solution in 30 patients with severe oral erosive lesions.. Over a 48-week period, we evaluated the evolution of pain, ulcerations, atrophy, and interference of the disease in the patient's daily life, classifying the response as complete (100% remission/recovery), excellent (75%), good (50%), poor (<50%), or failed.. The pain and ulceration totally disappeared in 93.3% of cases and 90% reported a full recovery in their daily life activities. Atrophy response was complete in 28.5%, excellent in 60.7%, and good in 3.5%. Two patients showed no response to the treatment. Five patients suffered mild adverse effects (moon face and hirsutism) between week 4 and week 6 of treatment, which were speedily reversed by reducing the frequency of mouthwash.. Clobetasol mouthwash is a safe and efficacious option for the treatment of severe oral erosive lesions.

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Clobetasol; Drug Administration Schedule; Female; Glucocorticoids; Humans; Lichen Planus, Oral; Male; Middle Aged; Mouth Mucosa; Mouthwashes; Pemphigoid, Benign Mucous Membrane; Stomatitis, Aphthous; Treatment Outcome

This study evaluated the clinical use of a corticosteroid in three preparations (topical clobetasol propionate ointment, clobetasol propionate in an oral analgesic base, and clobetasol propionate in an adhesive denture paste).. Fifty-four patients (34 males and 20 females) with a history of vesiculo-ulcero-erosive oral lesions were selected: 24 with oral erosive lichen planus and 30 with aphthae. The subjects enrolled were randomly divided into three groups, each of 18 patients (10 with aphthae and 8 with lichen planus): the first was treated with topical clobetasol propionate ointment (0.05%) directly on the lesion(s) three times a day; the second with clobetasol propionate in an adhesive denture paste in equal amounts (1:1) two times a day; the third with clobetasol propionate in an oral analgesic base (Orabase-B) in equal amounts (1:1) two times a day. Each subject scored his or her symptoms daily from most severe (7) to none (0) by verbal assessments using a categorical scale.. In all cases, the administration of the corticosteroid was effective in producing remission of symptoms in each group of patients. Significant differences (P<0.05) between groups were determined by the Kruskal-Wallis test. The Dunn test was used in order to detect which group differs from the others; clobetasol and adhesive denture paste correlated with an early remission of pain in lichen and apthous lesions.. The results suggest that topical application of clobetasol in an adhesive denture paste is an effective drug for symptomatic oral vesiculo-erosive and/or ulcerative lesions.

Topics: Adhesives; Administration, Topical; Adolescent; Adult; Anesthetics, Local; Anti-Inflammatory Agents; Benzocaine; Carboxymethylcellulose Sodium; Clobetasol; Female; Glucocorticoids; Humans; Lichen Planus, Oral; Male; Middle Aged; Ointments; Pilot Projects; Stomatitis, Aphthous

Clobetasol propionate (Temovate), a novel high-potency topical corticosteroid, was used in open trial from 1987 to 1988 on 24 patients with persistent oral vesiculoerosive disease of at least 1 month's duration. Fourteen women and 10 men, ranging in age from 27 to 76 years (mean 48 years), participated. Nine patients had erosive lichen planus, one had benign mucous membrane pemphigoid, three had pemphigus vulgaris, seven had persistent major recurrent aphthous stomatitis, and four had chronic oral erythema multiforme. Fifteen patients had complete remission of signs and symptoms, seven had excellent response of signs and complete remission of symptoms, and two failed to respond. All other topical therapy was suspended before and during the study. All patients responded to two or three applications daily of medication. Side effects were minor and reversible, and included localized candidiasis (three patients), stomatopyrosis (two), and hypogeusia (one). Clobetasol propionate ointment in adhesive paste (Orabase) thus seems to be an effective topical steroid alternative to other less potent topical and systemic drugs for recalcitrant oral vesiculoerosive disease.

Topics: Adult; Aged; Clobetasol; Female; Humans; Hydrocortisone; Lichen Planus; Male; Middle Aged; Mouth Diseases; Pemphigoid, Benign Mucous Membrane; Pemphigus; Stomatitis, Aphthous

This report describes a young black Caribbean woman with a three-year history of recurrent genital ulceration initially diagnosed as genital herpes. This diagnosis had been made clinically by the general practitioner but never confirmed on culture or nucleic acid amplification testing; sequential treatment with aciclovir and famciclovir over a four-month period did not alleviate her genital symptoms. Presentation to our genitourinary (GU) medicine clinic identified painful aphthous genital and oral ulcers, erythema nodosum bilaterally and a history of eye irritation. A clinical diagnosis of Behçet's disease was made. Treatment with hydrocortisone mouth pellets and dermovate ointment was initiated in addition to dermatology and ophthalmology referral. This report reminds clinicians to consider alternative diagnoses in clinical practice when faced with patients who are resistant to treatment. It also highlights the importance of recognizing systemic disease and maintaining a holistic approach when treating patients.

Topics: Adult; Behcet Syndrome; Clobetasol; Diagnosis, Differential; Female; Humans; Hydrocortisone; Oral Ulcer; Stomatitis, Aphthous; Ulcer; Vulvar Diseases

We sought to describe the response of patients with severe erosive gingival lesions to treatment with clobetasol propionate in Orabase paste administered in trays. The adverse effects were also recorded.. A descriptive pretest/posttest clinical study with no control group (33 patients total) was developed. All patients received repeated applications of 0.05% clobetasol propionate plus 100,000 IU/cc of nystatin in Orabase paste. Over the 48-week period, the pain levels, ulcerations, presence of atrophy, and the patients' daily activities were recorded, and Likert scales were used to classify each outcome as either a complete recovery, excellent, good, poor, or failed. The presence of any adverse effect was also noted.. At the end of the study period, the pain and ulceration had disappeared (complete response) in 100% of the sample (33/33; 95% confidence interval = 89.4%-100%), and there was a complete recovery of daily activities and remission of atrophy in 93.9% (31/33; 95% confidence interval = 79.8%-99.3%) and 21.2% (7/33; 95% confidence interval = 9.0%-38.9%) of the patients, respectively. No adverse effects related to the treatment were observed.. The application of an Orabase paste of 0.05% clobetasol 17-propionate plus 100,000 IU/cc of nystatin by means of a tray appears to be an efficacious treatment for severe erosive gingival lesions.

Topics: Activities of Daily Living; Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Autoimmune Diseases; Clobetasol; Confidence Intervals; Drug Combinations; Female; Follow-Up Studies; Gingival Diseases; Glucocorticoids; Humans; Lichen Planus, Oral; Male; Middle Aged; Nystatin; Pain Measurement; Patient Satisfaction; Pemphigoid, Benign Mucous Membrane; Stomatitis, Aphthous

Topics: Adhesives; Administration, Topical; Anti-Inflammatory Agents; Clobetasol; Drug Carriers; Follow-Up Studies; Glucocorticoids; Humans; Lichen Planus, Oral; Recurrence; Stomatitis, Aphthous; Treatment Outcome

Topics: Administration, Topical; Anesthetics, Local; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cellulose; Clobetasol; Drug Combinations; Glucocorticoids; Humans; Lidocaine; Nystatin; Recurrence; Sorbic Acid; Stomatitis, Aphthous; Time Factors

Recurrent aphthous ulcers in patients with HIV infection can cause significant morbidity, which makes successful diagnosis and treatment imperative. We have found that the diagnostic paradigm for recurrent aphthous ulcers in HIV-seronegative patients, which is based on the ulcers' clinical appearance, location, absence of other ulcer-causing pathogens or pathogenic processes, and response to therapy, may be successfully applied to recurrent aphthous ulcers in HIV-infected patients. However, one must be alert for ulcers with uncommon causes as well as ulcers with common causes that have atypical clinical appearances that may mimic recurrent aphthous ulcers. The topical glucocorticoids, which are used to treat recurrent aphthous ulcers in HIV-seronegative patients, proved very effective in HIV-infected patients for treatment of herpetiform and minor ulcers and most major ulcers and were without notable side effects. A few severe cases of major recurrent aphthous ulcers required treatment with systemic prednisone, and some side effects were encountered.

Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Dexamethasone; Female; Fluocinonide; Glucocorticoids; HIV Infections; Humans; Male; Middle Aged; Prednisone; Stomatitis, Aphthous